ADXS News Alert Advaxis Inc (ADXS) 7.57 12/25/2014 15:05:03

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Advaxis Inc (ADXS) 7.57 $ADXS

Nasdaq stocks posting largest volume increases
AP - Tue Dec 23, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
INTG: 17.90 (+0.01), NICK: 14.80 (+0.20), ADXS: 7.57 (+0.50), WBKC: 23.47 (+0.03), SOCB: 7.20 (+0.03), CBIN: 27.50 (-0.28), UPI: 2.30 (unch), CTIB: 3.74 (-0.06), SONA: 11.29 (unch)

Nasdaq stocks posting largest percentage increases
AP - Tue Dec 23, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
CYTK: 5.87 (+0.35), RDUS: 37.17 (+0.11), NICK: 14.80 (+0.20), VSAR: 22.25 (-0.11), ADXS: 7.57 (+0.50), VNDA: 14.69 (+1.11), CZR: 15.44 (+0.20)

Advaxis continues cancer immunotherapy-stoked up move
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 11:58AM CST

ADXS: 7.57 (+0.50), AZN: 70.44 (+0.26)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 11:50AM CST

ADXS: 7.57 (+0.50), SANW: 3.98 (-0.02), ASPS: 33.81 (+4.37), OCN: 14.88 (-0.14), ZAZA: 3.20 (+0.70), SGOC: 0.61 (-0.02), AAMC: 335.99 (-4.00), VOC: 5.60 (-0.09), TECU: 3.59 (-0.14), RDUS: 37.17 (+0.11), IRMD: 12.64 (+0.14), SKYS: 11.05 (-0.95), VSCI: 0.76 (-0.07), CALA: 22.33 (+1.16), REXX: 5.17 (-0.17), CFRX: 3.99 (+0.10), TRXC: 2.79 (+0.03), CHNR: 1.92 (-0.15), CNET: 1.28 (-0.11), DRYS: 1.20 (-0.04)

Pharma Deals Watch: Coverage Initiated on AstraZeneca, Advaxis, Radius Health, Cubist and AbbVie
PR Newswire - Mon Dec 22, 8:00AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including AstraZeneca (NYSE: AZN), Advaxis (NASDAQ: ADXS), Radius Health (NASDAQ: RDUS), Cubist (NASDAQ: CBST), and AbbVie (NYSE: ABBV). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
RDUS: 37.17 (+0.11), ADXS: 7.57 (+0.50), CBST: 100.29 (-0.09), AZN: 70.44 (+0.26), ABBV: 66.21 (+1.86)

Advaxis Completes $17 Million Financing
GlobeNewswire - Fri Dec 19, 2:34PM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that it has executed definitive securities purchase agreements with two institutional investors for gross proceeds of approximately $16.7 million in a registered direct offering of approximately 3.9 million shares at a price of $4.25 per share.
ADXS: 7.57 (+0.50)

Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-HPV in Combination With MedImmune's MEDI4736 for the Treatment of HPV-Associated Cancers
GlobeNewswire - Mon Dec 15, 6:39AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a Phase 1/2 clinical study of ADXS-HPV (ADXS11-001) alone or in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, for the treatment of advanced, recurrent or refractory human papillomavirus (HPV)-associated cervical cancer and HPV-associated head and neck cancer. The trial is expected to begin patient enrollment in early 2015.
ADXS: 7.57 (+0.50)

Advaxis's Cancer Immunotherapies Featured on FOX News
GlobeNewswire - Fri Dec 12, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced that its Lm-LLO immunotherapy technology is featured on FOX News Channel in a broadcast segment and article, entitled, "Teaching the immune system to fight back against cancer."
ADXS: 7.57 (+0.50)

Advaxis's Listeria-based Lm-LLO Immunotherapy Featured in Nature Biotechnology
GlobeNewswire - Thu Dec 11, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that its Lm-LLO immunotherapy technology is featured in an article in the December 2014 issue of Nature Biotechnology. Entitled "Listeria vaccines join the checkpoint frenzy," the article explores the potential of the Listeria bacterium as a vector to enhance an anti-tumor response given its ability to induce powerful innate and adaptive immune responses.
ADXS: 7.57 (+0.50)

Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-PSA in Combination With Merck's KEYTRUDA(R) (pembrolizumab) for Prostate Cancer
GlobeNewswire - Mon Dec 08, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a Phase 1/2 clinical study to evaluate the combination of ADXS-PSA (ADXS31-142) with KEYTRUDA (pembrolizumab), marketed by Merck & Co., Inc., in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC). The clinical trial, which will be the first-in-human study of Advaxis's lead Lm-LLO immunotherapy product candidate in prostate cancer, is expected to begin patient enrollment in the first quarter of 2015.
ADXS: 7.57 (+0.50), MRK: 57.46 (+0.25)

InMed Pharma's Hiring of Tiberend Highlights Biotech Focus
ACCESSWIRE - Wed Dec 03, 9:32AM CST
WHITEFISH, MT / ACCESSWIRE / December 3, 2014 / Cannabis based medicine is being widely adopted as the next exciting special interest sector of the biotech community. With GW Pharmaceuticals plc (NASDAQ: GWPH) and others conducting clinical trials targeting important indications like cancer pain and arthritis, the data collected so far has suggested that cannabinoids could have far-reaching beneficial effects on the human body.
ADXS: 7.57 (+0.50), GWPH: 68.08 (+1.82), GALE: 1.49 (-0.02)

Advaxis to Present at the LD Micro Conference
GlobeNewswire - Tue Nov 25, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that it will present at the LD Micro Conference being held December 2-4, 2014 at the Luxe Hotel in Los Angeles, California.
ADXS: 7.57 (+0.50)

MarketExclusive.com - Nobel Financial Reiterates Buy Rating of Advaxis, Inc. Based on a Review of Recent Data Presentations and IND Submissions
ACCESSWIRE - Mon Nov 24, 11:45AM CST
NEW YORK, NY / ACCESSWIRE / November 24, 2014 / Market Exclusive announces that Nobel Financial has reiterated a Buy rating of Advaxis, Inc. (Nasdaq: ADXS) with a 12-month target price of $12. The Buy rating is based on a review of recent data presentations and IND submissions.
ADXS: 7.57 (+0.50)

Advaxis, Inc. - "From Two Checkpoint Inhibitor Development Agreements to Two IND Filings in Four Months - A Special Thanksâ?¦"
ACCESSWIRE - Mon Nov 24, 7:23AM CST
New York, NY / ACCESSWIRE / November 24, 2014 / Advaxis, Inc. (NASDAQ: ADXS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Daniel J. O'Connor. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
ADXS: 7.57 (+0.50)

Advaxis to Receive $1.7M Through New Jersey Technology Business Tax (NOL) Program
GlobeNewswire - Thu Nov 20, 6:36AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced it has received preliminary approval for a $1.9M tax credit from the New Jersey Technology Business Tax Certificate Transfer (NOL) Program for the year 2014. The Company anticipates that it will be able to transfer this credit and receive approximately $1.7 million in cash in mid-December.
ADXS: 7.57 (+0.50)

Global Cervical Cancer Therapeutic Pipeline Review, H2 2014 - 35 Companies & 71 Drug Profiles
M2 - Wed Nov 19, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/4p52hn/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - Nektar Therapeutics - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Amorfix Life Sciences Ltd. - MediGene AG - Nanotherapeutics, Inc. - Arbor Vita Corporation - Novartis AG - Chong Kun Dang Pharmaceutical Corp. - Taiho Pharmaceutical Co., Ltd. - Zeria Pharmaceutical Co Ltd - Genmab A/S - Advaxis, Inc. - 3SBio Inc. - Transgene SA - Antigen Express, Inc. - Shantha Biotechnics Limited - Bionor Pharma ASA - Azaya Therapeutics Incorporated - Merrimack Pharmaceuticals, Inc. - Genexine, Inc. - Genticel - Sirnaomics, Inc. - EyeGene, Inc. - Vaccibody AS - Wellstat Biologics Corporation - ISA Pharmaceuticals B.V. For more information visit http://www.researchandmarkets.com/research/4p...cal_cancer
MACK: 10.91 (+0.36), INO: 9.11 (-0.09), ADXS: 7.57 (+0.50), GSK: 42.85 (+0.11), NKTR: 15.02 (+0.23), NVS: 93.91 (+0.66)

Advaxis Is Undervalued With Multiple Partnerships And Near-Term Commercialization Potential In 2015
Tony Schwartz, PhD - at Seeking Alpha - Thu Nov 13, 1:51PM CST

ADXS: 7.57 (+0.50)

Advaxis submits IND for HPV-associated cancers
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 10:13AM CST

ADXS: 7.57 (+0.50), AZN: 70.44 (+0.26)

Advaxis Submits Investigational New Drug Application for Phase 1/2 Study of ADXS-HPV and MedImmune's MEDI4736 for the Treatment of HPV-Associated Cervical and Head & Neck Cancer
GlobeNewswire - Wed Nov 12, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the Company has submitted an Investigational New Drug application (IND) to the United States Food and Drug Administration (FDA) to conduct a Phase 1/2 study of ADXS-HPV (ADXS11-001) alone or in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, for the treatment of advanced, recurrent or refractory human papillomavirus (HPV)-associated cervical cancer and HPV-associated head and neck cancer.
ADXS: 7.57 (+0.50)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bill Targets 15% Federal Goal for Women-Owned Firms

Updated Category News Views 28

Federal procurement has a stubborn habit of sounding abstract until you remember that contracts can decide whether a small company hires, invests, or simply keeps the lights on. Senator Adam Schiff introduced the Women's Economic Fairness and Small Business Contracting Act on November 19, 2026, proposing to raise the federal goal for Women-Owned Small Businesses from 5%...

Continue Reading
Vizsla's Panuco Delay Puts Security Ahead of Speed

Updated Category News Views 110

A mine schedule can absorb a calendar slip; the people around a mine cannot be treated like a line item. Vizsla Silver's update on Panuco is therefore not the usual development-company chest thumping. It is a sober admission that security, permitting and site readiness have pushed first silver to the second half of 2028, one year later than the prior H2 2027 target....

Continue Reading
Lowe's Dec. 9 Conference Puts Strategy on the Clock

Updated Category News Views 0

A Calendar Entry With Real Weight December 9 is not earnings day, but it is the sort of date shareholders ought to circle anyway. Lowe's plans to hold its 2026 Analyst and Investor Conference at 8 a.m. Eastern time in New York City, with a live webcast available for those not sitting in the room. For owners of NYSE:LOW, these gatherings can be more useful than the usual...

Continue Reading
Corner Bakery Bets on Holiday Catering Convenience

Updated Category News Views 51

A $50 carrot on a $350 catering tab tells you exactly where Corner Bakery sees the holiday battlefield: not in one lonely cookie sale, but in the larger group order that can make a restaurant’s day. The chain is pushing holiday catering through November and December, pairing that discount with bakery trays, meals for groups and a promise to handle delivery setup. It is...

Continue Reading
A Quanzhou Table Offers China Beyond the Headlines

Updated Category News Views 150

Steam rising from a Quanzhou table can carry more weight than another polished speech about cultural exchange. That is the sensible instinct behind Home Banquets with Master Chefs, the CCTV-4 series using regional meals to explore geography, customs and memory. It is not trying to explain China through a pile of statistics or a museum-label summary. It starts where people...

Continue Reading
Receipts Turns Vegas Party Shirts Into AR Keepsakes

Updated Category News Views 118

A shirt that coughs up a Vegas weekend when scanned is either a smart little keepsake trick or a privacy headache wearing sequins. Receipts™, introduced by Las Vegas-based Naked City Couture and the AR Trading Card Company, is betting it can be the former. The concept is simple enough: friends wear the apparel, capture photos and videos during a trip, upload those...

Continue Reading
PARRIS Partners Earn 2026 Plaintiff Lawyer Recognition

Updated Category News Views 95

A $58.4 million jury number can make a courtroom sound like a slot machine, until the final settlement lands at $21 million. That gap is the part people ought to stare at before getting carried away by another plaintiff-lawyer honor roll. The Daily Journal has named PARRIS Law Firm partners Alexander R. Wheeler and Khail A. Parris to its 2026 Top Plaintiff Lawyers special...

Continue Reading
Yiwu Squishies Turn Viral Demand Into Factory Backlogs Worldwide

Updated Category News Views 55

A pizza-shaped stress toy booking more than one million units is the sort of detail that makes a jaded market watcher sit up before rolling his eyes at the word “viral.” Yiwu’s squishy-toy surge appears to have moved beyond a few social-media impulses and into actual factory scheduling, repeat purchase orders and supermarket procurement. That is meaningful. It is...

Continue Reading
Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 17

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
ROHM's GaN PFC Chip Targets the Power-Supply Squeeze

Updated Category News Views 118

Power supplies are where a lot of sleek electronics quietly lose the plot, and ROHM is taking a proper swing at that problem. Its new BM85060FV is a totem-pole power factor correction controller built for gallium nitride, or GaN, high-frequency switching in AC-DC power supplies. The headline is not subtle: ROHM says a 300 to 500 W system using the chip can reach 99%...

Continue Reading

Top 5 Most Recently Viewed Articles

Addgene Launches Innovative Antibody Characterization Platform

Updated Category News Views 109

Addgene Launches Innovative Antibody Characterization Platform Addgene, a visionary organization dedicated to enhancing scientific research, recently introduced a groundbreaking antibody characterization platform that draws from its extensive antibody catalog. This initiative aims to significantly advance the field of biomedical research by ensuring that antibodies are...

Continue Reading
Nishant Saxena Joins Jeune Aesthetics as CFO to Drive Growth

Updated Category News Views 294

Jeune Aesthetics Welcomes New Chief Financial Officer Jeune Aesthetics has taken a significant step forward by appointing Nishant Saxena as its Chief Financial Officer (CFO). This decision comes at a crucial time as the company prepares to advance its growth strategies and innovate in the field of medical aesthetics designed to combat aging skin. Understanding the...

Continue Reading
Organ Preservation Solutions Market to Reach $512.62 Million by 2031

Updated Category News Views 144

Growth of the Organ Preservation Solutions Market The organ preservation solutions market is experiencing significant growth as the global demand for organ transplantation rises. According to a comprehensive report from The Insight Partners, it is projected that this market will reach a remarkable $512.62 million by 2031 with a compound annual growth rate (CAGR) of 8.1%....

Continue Reading
Alpine Income Property Trust Secures $14.1 Million Mortgage Loan

Updated Category News Views 133

Alpine Income Property Trust Makes Strategic Mortgage Investment WINTER PARK, Fla. – Alpine Income Property Trust, Inc. (NYSE: PINE), a well-known real estate investment trust, has recently announced a significant investment by originating a first mortgage loan. The loan investment, amounting to $14.1 million, is secured by a luxury residential development featuring...

Continue Reading
Zenity Introduces New Framework for Securing GenAI Systems

Updated Category News Views 127

Zenity Introduces GenAI Attacks Matrix for Enhanced Security Zenity, a leader in the security domain for enterprise copilots and low-code development, has launched its innovative security framework known as the GenAI Attacks Matrix. This open-source initiative is inspired by the renowned MITRE ATLAS and developed with contributions from top security researchers worldwide,...

Continue Reading